Refnot® – novyy immunomodulyator dlya lecheniya onkologicheskikh bol'nykh

The article presents the data from clinical trials of the original domestic combined immunomodulator for cancer patients - tumor necrosis factor - thymosin alpha-1 recombinant (Refnot®). The results of these studies have demonstrated the unique immunomodulatory properties of Refnot. Features of this drug, differing from other known immunomodulators, include the positive impact simultaneously on the two cell populations - T- and NK-cells, which are the major components of the anti-tumor immunity. The use of Refnot® is recommended as monotherapy and in combination with cytotoxic drugs in cancer patients as an immunomodulator.

tumor necrosis factor - thymosin alpha-1 recombinant, Refnot®, malignant tumors, immunomodulatory action, T- lymphocytes, natural killer cells